explore -WSS

explore

author：comprehensive 2025-09-02 11:48:20 - browse：729

Mifepristone (Mifeprex) and Misoprostol — A federal appeals court on Wednesday ruled to restrict access to the abortion pill mifepristone but not remove it from the market entirely. ROBYN BECK/AFP via Getty Images

A federal appeals court on Wednesday ruled to restrict access to the abortion pill mifepristone but not remove it from the market entirely, partially upholding a lower court’s decision.

The decision from the three-judge panel of the 5th U.S. Circuit Court of Appeals would effectively block mail-order prescriptions of the pill. However, access will remain unchanged for now, as the Supreme Court issued an emergency order this spring to preserve the status quo while the case goes through the appeals process.

The case is all but assured to head to the highest court, which last year overturned Roe v. Wade. Since the ruling, 14 states have implemented abortion bans and another 11 have imposed limits, some up to six weeks of pregnancy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： How I ended up pumping milk in a bathroom stall at JPM 2024

hotspot

WSS

New safety details link Apellis eye drug to rare cases of blindness

National panel will explore requiring free Covid tests

Fauci’s Covid grilling leads GOP to weigh foreign research rules

No plane should take off without an EpiPen onboard

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

Amazon expands telehealth clinic nationwide

hotspot

explore

entertainment

Moonlake's readout produced a cash windfall. Risks remain

The nurse manager staffing crisis is hurting patients

At least 13 dead in Texas as scorching temps continue

Three issues to watch in global health in 2024

Heart attack and stroke risk calculators need revising

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

Duchenne breakthrough therapy leaves behind pioneering families

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

Affirmative action in medical school literally saved lives

What the US credit downgrade means for the economy, your finances

entertainment

Health and fitness trackers are measuring the wrong things

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

DeSantis can now import cheaper drugs. But will Biden get credit?

What the airline industry can learn from medicine

Amazon expands telehealth clinic nationwide

Infectious disease expert Jeanne Marrazzo assumes Fauci role

knowledge

hotspot

focus

entertainment